Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Group 1 - The company, Hanyu Pharmaceutical, announced that it will hold a board and supervisory board meeting on September 25, 2025, to review the proposal for a specific issuance of A-shares [1] - The relevant proposal and announcement have been disclosed on the Giant Tide Information Network [1] - The issuance of shares is subject to approval by the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1]

Core Viewpoint - Hanyu Pharmaceutical (300199.SZ) plans to issue A-shares to specific investors, aiming to raise up to 968 million yuan for various projects and working capital [1] Group 1: Share Issuance Details - The company intends to issue shares to no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the 20 trading days prior to the pricing benchmark [1] - The total number of shares issued will be determined by dividing the total amount raised by the issuance price, not exceeding 30% of the total share capital before the issuance [1] Group 2: Use of Proceeds - The raised funds will be allocated entirely to the expansion of peptide drug production lines and green intelligent upgrades, expansion of peptide fragment production, upgrading of research laboratories, development of Semaglutide, and to supplement working capital [1]

Core Viewpoint - Hanyu Pharmaceutical plans to raise a total of up to RMB 968 million through a private placement, with the net proceeds allocated to various projects including peptide drug production and R&D upgrades [1] Fundraising Purpose - The funds will be used for the expansion of peptide drug production lines and green intelligent upgrades [1] - Additional allocations include the construction of peptide fragment production projects and the upgrade of R&D laboratories [1] - Specific projects also include the development of Semaglutide and its domestic injectable and oral formulations for diabetes treatment [1] - A portion of the funds will be used to supplement working capital [1]

Core Viewpoint - Han Yu Pharmaceutical plans to raise no more than 968 million yuan through a private placement of A-shares, aimed at addressing project investment and R&D funding needs, thereby alleviating financial pressure and enhancing risk resilience [1] Fundraising Details - The company intends to use the net proceeds from the fundraising for multiple projects, including the expansion of peptide drug production lines, green intelligent upgrades, peptide fragment production expansion, laboratory upgrades, and the development of Semaglutide [1] Financial Implications - The fundraising is expected to help the company manage its operational and R&D activities more effectively, ensuring a reasonable arrangement of resources and improving its ability to withstand financial risks [1]

每经头条（nbdtoutiao）——"9·24"一周年，A股总市值破116万亿元！四大变革重塑中国资本市场新生 态 （记者 张喜威） 每经AI快讯，翰宇药业9月25日晚间发布公告称，公司第六届第七次董事会会议于2025年9月25日在公 司龙华总部2006董事会会议室以现场结合通讯方式召开。会议审议了《关于公司2025年度向特定对象发 行股票方案的议案》等文件。 ...

Core Viewpoint - Han Yu Pharmaceutical announced the approval of a private placement of A-shares, aiming to raise up to RMB 968 million for various projects, while cautioning investors about potential uncertainties in the process [1] Summary by Categories Fundraising Details - The private placement will involve no more than 35 specific investors [1] - The issuance price will be no less than 80% of the average trading price of the company's stock over the 20 trading days prior to the pricing date [1] - The total amount to be raised is up to RMB 968 million [1] Allocation of Funds - The funds will be allocated to several projects: - Peptide drug production line and green intelligent expansion project: Total investment of approximately RMB 549 million, with RMB 495 million from the raised funds [1] - Peptide fragment expansion construction project: Total investment of RMB 45.8 million, with RMB 40 million from the raised funds [1] - R&D laboratory upgrade project: Total investment of RMB 57.75 million, with RMB 55 million from the raised funds [1] - Semaglutide R&D project: Total investment of approximately RMB 133 million, with RMB 98 million from the raised funds [1] - Semaglutide domestic injection (for diabetes indication) project: Total investment of RMB 57 million, with RMB 25 million from the raised funds [1] - Semaglutide oral tablet (for diabetes indication) project for the U.S. market: Total investment of RMB 75.8 million, with RMB 73 million from the raised funds [1]

证券代码：300199 证券简称：翰宇药业 公告编号：2025-044 采取监管措施或处罚及整改情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年9月25日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇 药业"）第六届董事会第七次会议、第六届监事会第四次会议审议通过了关于公 司2025年度向特定对象发行A股股票的相关议案。公司对近五年是否被证券监管 部门和证券交易所采取监管措施或处罚的情况进行了自查，自查结果如下： 一、最近五年被证券监管部门和交易所采取处罚的情况 公司最近五年不存在被证券监管部门和证券交易所处罚的情况。 二、公司最近五年被证券交易所纪律处分的情况 （一）2021年9月1日深圳证券交易所出具的《关于对深圳翰宇药业股份有限 公司及相关当事人给予通报批评处分的决定》 公司于2021年9月1日收到深圳证券交易所出具的《关于对深圳翰宇药业股份 有限公司及相关当事人给予通报批评处分的决定》，公司因2020年度业绩预告披 露的预计净利润与2020年年度报告经审计的净利润相比，盈亏性质发生变化、存 在重大差异且未及时修正，公司违反了 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-046 深圳翰宇药业股份有限公司 关于增加2025年度向金融机构申请综合授信及担保额度的 议案 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年9月25日，深圳翰宇药业股份有限公司（以下简称"公司"）召开第 六届董事会第七次会议，审议通过了《关于增加2025年度向金融机构申请综合授 信及担保额度的议案》。具体情况如下： 三、备查文件 《第六届董事会第七次会议决议》； 特此公告。 2025年2月28日及2025年3月17日，公司召开第六届董事会第二次会议及2025 年年度股东大会，审议通过《关于2025年度向金融机构申请综合授信及担保额度 的议案》，公司及控股子公司2025年度向金融机构申请综合授信及担保总额度不 超过3.5亿元，有效期为自公司2025年第一次临时股东大会审议通过之日起12个 月内，授信及担保期限内额度可循环使用。 二、本次拟增加综合授信及担保额度的情况 结合当前公司实际情况及经营规划，为满足公司及控股子公司日常生产经营 的需求，2025年度公司及控股子公司拟向金融机构申请 ...

鉴于公司最近五个会计年度（2020-2024 年）不存在通过配股、增发、可转 换公司债券等方式募集资金的情况，公司前次募集资金到账时间距今已超过五个 会计年度。因此公司本次向特定对象发行股票无需编制前次募集资金使用情况报 告，亦无需聘请会计师事务所出具前次募集资金使用情况鉴证报告。 特此公告。 深圳翰宇药业股份有限公司 关于无需编制前次募集资金使用情况报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《监管规则适用指引——发行类第 7 号》有关规定："前次募集资金使 用情况报告对前次募集资金到账时间距今未满五个会计年度的历次募集资金实 际使用情况进行说明，一般以年度末作为报告出具基准日，如截止最近一期末募 集资金使用发生实质性变化，发行人也可提供截止最近一期末经鉴证的前募报 告。" 证券代码：300199 证券简称：翰宇药业 公告编号：2025-042 深圳翰宇药业股份有限公司董事会 2025 年 9 月 26 日 ...